Custom service
Peptide-Modified Liposome and LNP Delivery Services
Modify liposomes and lnps with peptides for targeted delivery
Peptide-Modified Liposome and LNP Delivery Services supports programmes that modify liposomes and LNPs with peptides for targeted delivery. In a typical engagement we plan the post-insertion and pre-formulation peptide anchoring route first, confirm compatibility with ligand-density optimization, and release peptide-modified formulation with targeting and EE data on a 5–10 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep post-insertion and pre-formulation peptide anchoring as the primary option and hold ligand-density optimization in reserve, so that scale-up never depends on an unproven step.
LNP targeting-ligand screening
Liposome surface engineering
Clinical-batch LNP manufacturing
In-vivo dosing campaigns without a completed in-vitro validation stage
Delivery programmes are released in two layers: chemical (identity, purity, payload loading) and functional (uptake, knockdown or transfection readout in the agreed cell model). Both layers are documented, because a construct that is chemically perfect but functionally silent is a failure.
Service Highlights
- Post-insertion and pre-formulation peptide anchoring as the default route, with ligand-density optimization held as a proven fallback
- Encapsulation-efficiency QC worked into the design where the application requires it
- Every delivery construct is validated for uptake or knockdown function, not just characterized chemically
- Analytical confirmation of every intermediate before the final release
- Serum-stability and competitive-serum conditions are part of the standard test matrix
- Peptide-modified formulation with targeting and EE data delivered with a complete conjugation or synthesis certificate
How the work runs
Payload & target review
Payload chemistry, target cell and readout are agreed; Peptide-Modified Liposome and LNP Delivery Services concept routes are drafted.
Construct design
Peptide ligand, linker and presentation are designed; post-insertion and pre-formulation peptide anchoring is selected.
Assembly
The construct is assembled and purified chemically, with payload loading quantified.
Functional validation
Uptake or knockdown is measured in the target cell model, with ligand-density optimization controls.
Stability & optimization
Serum stability and iteration rounds tune the design to the agreed specification.
Release & hand-off
Peptide-modified formulation with targeting and EE data plus the validation report is released with a handling SOP.
Specifications & timeline
- Turnaround
- 5–10 weeks
- Typical scale
- mg-scale construct plus validation report
- Chemistry options
- post-insertion and pre-formulation peptide anchoring; ligand-density optimization; encapsulation-efficiency QC
- Deliverable
- Peptide-modified formulation with targeting and EE data
- QC package
- Chemical QC plus functional uptake/delivery assay data
- Shipping
- Blue ice, aliquoted, with handling SOP
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.